EverSource Wealth Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

EverSource Wealth Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.58K	Sell	4,027 -189	-4%	-$325	﹤0.01%	2988
2026 Q1	$7.13K	Sell	4,216 -413	-9%	-$1.81K	﹤0.01%	3096
2025 Q4	$24K	Sell	4,629 -211	-4%	-$1.08K	﹤0.01%	2268
2025 Q3	$25.3K	Buy	4,840 +291	+6%	+$1.52K	﹤0.01%	2185
2025 Q2	$17.4K	Buy	4,549 +4,152	+1,046%	+$10.7K	﹤0.01%	2406
2025 Q1	$2.28K	Buy	397 +382	+2,547%	+$2.26K	﹤0.01%	2865
2024 Q4	$75	Buy	+15	New	+$77	﹤0.01%	3590
2022 Q2	–	Sell	-213	Closed	-$1K	–	1703
2022 Q1	$1K	Hold	213	–	–	﹤0.01%	1622
2021 Q4	$1K	Buy	+213	New	+$1.62K	﹤0.01%	1672

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

EverSource Wealth Advisors's ALDX Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Aldeyra Therapeutics (ALDX) stake by 4.5% in Q2 2026, selling an estimated $325 and leaving 4,027 shares worth $8.58K. The position accounts for ﹤0.01% of the portfolio, ranked #2988.

EverSource Wealth Advisors first reported a position in ALDX in Q4 2021 and has held it in 9 quarters since. The position peaked at $25.3K in Q3 2025. 107 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

EverSource Wealth Advisors held 4,027 shares of Aldeyra Therapeutics worth $8.58K as of Q2 2026.
EverSource Wealth Advisors sold 189 Aldeyra Therapeutics shares in Q2 2026, an estimated $325.
Aldeyra Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #2988 holding.
EverSource Wealth Advisors first reported a position in Aldeyra Therapeutics in Q4 2021 and has held it in 9 quarters since.
EverSource Wealth Advisors's Aldeyra Therapeutics position peaked at $25.3K in Q3 2025.
107 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.